Tauro ursodeoxycholic acid (TUDCA) inhibits human fibrosarcoma HT-1080 cell invasion through MMPs inactivation and the modulation of the MAPKs signaling pathway | Synapse
March 3, 2026Open Access
Tauro ursodeoxycholic acid (TUDCA) inhibits human fibrosarcoma HT-1080 cell invasion through MMPs inactivation and the modulation of the MAPKs signaling pathway
Key Points
TUDCA significantly reduces fibrosarcoma HT-1080 cell invasion through MMPs inhibition.
Inhibition of MMP activity was observed, leading to decreased invasion rates by more than 50%.
Analysis of MAPK signaling pathway showed modulation in response to TUDCA treatment, revealing functional changes.
Future studies should explore TUDCA's potential as a therapeutic agent against fibrosarcoma, with broader clinical implications.